The Journal of the American Medical Association shows up on this site when its research shapes how GLP-1s and peptides are used, sold, and governed. Its coverage has clustered around two themes: treatment standards and access safety.
On the standards side, a JAMA Special Communication helped anchor the WHO's GLP-1 obesity treatment guidance in 2026. On the access side, a June 2026 JAMA Viewpoint warned that the online injectable-peptide surge had outrun regulation, and a July 2026 secret-shopper study led by a Yale researcher put numbers to that concern: across 49 websites selling branded or compounded semaglutide or tirzepatide, 45 (91.8%) issued a prescription, with a median time to prescription of a day or less and often minimal clinical evaluation.
Stories tagged here point to JAMA studies and commentary relevant to GLP-1 efficacy, peptide safety, and the prescribing practices behind the boom. See #glp-1, #telehealth, and #semaglutide.
A JAMA study led by a Yale researcher, reported by STAT on July 6, had an investigator pose as a patient across 49 websites selling branded or compounded semaglutide or tirzepatide between August and December 2025. Of those, 45 sites (91.8%) issued a prescription, with a median time to prescription of one day or less and often minimal clinical evaluation. The findings sharpen concerns about telehealth prescribing standards as enforcement against compounded GLP-1s tightens.
A JAMA Viewpoint published June 15 by researchers from the University of Queensland, the University of Toronto, and the University of California, San Francisco flagged a fast-growing but poorly characterized trend: social-media-promoted injectable peptides for muscle growth, recovery, anti-aging, and cognition. The piece notes 130,000-plus Instagram posts and over 230 million TikTok views as of May 2026, plus a 6x rise in worldwide Google searches for 'peptides' between 2024 (1.3M/month) and 2026 (~8M/month). Substances cited include BPC-157, TB-500, and CJC-1295. The authors call for accelerated safety research and clearer regulation; the piece lands six weeks before the July 23-24 PCAC meeting that will weigh seven of those same substances for 503A compounding status.
WHO's December 2025 first-ever GLP-1 guideline for obesity treatment in adults — published as a JAMA Special Communication and updated through Q1 2026 — continues to influence national and payer policy. WHO issued conditional recommendations for chronic GLP-1 therapy as part of comprehensive obesity management, while flagging cost, long-term safety, health-system preparedness, and equity implications. The framework directly informs the political economy of the U.S. Medicare Bridge program extension to 2027 and similar coverage debates globally.